Euroopan unioni - suomi - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - multiple myeloma - antineoplastiset aineet - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

eurogenerics holdings b.v. - teriparatidi - osteoporoosi - kalsiumin homeostaasi - qutavina is indicated in adults. osteoporoosin hoito postmenopausaalisilla naisilla ja miehillä, joilla on lisääntynyt murtumisriski. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. hoito osteoporoosi liittyy pitkäaikaiseen, systeemiseen glukokortikoidihoitoon naisilla ja miehillä on suurempi riski saada murtuma.

Euroopan unioni - suomi - EMA (European Medicines Agency)

theramex ireland limited - teriparatidi - osteoporoosi - kalsiumin homeostaasi - livogiva is indicated in adults. osteoporoosin hoito postmenopausaalisilla naisilla ja miehillä, joilla on lisääntynyt murtumisriski. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. hoito osteoporoosi liittyy pitkäaikaiseen, systeemiseen glukokortikoidihoitoon naisilla ja miehillä on suurempi riski saada murtuma.

Suomi - suomi - Fimea (Suomen lääkevirasto)

livisto int'l, s.l. - tulathromycin - injektioneste, liuos - 100 mg/ml

Euroopan unioni - suomi - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - multiple myeloma - antineoplastiset aineet - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiset suidaeille - siat (lihotus) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Euroopan unioni - suomi - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiset aineet - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple myeloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatidi - osteoporoosi - kalsiumin homeostaasi - sondelbay is indicated in adults. osteoporoosin hoito postmenopausaalisilla naisilla ja miehillä, joilla on lisääntynyt murtumisriski. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. hoito osteoporoosi liittyy pitkäaikaiseen, systeemiseen glukokortikoidihoitoon naisilla ja miehillä on suurempi riski saada murtuma.

Euroopan unioni - suomi - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multiple myeloma - antineoplastiset aineet - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.